•  
  •  
 

Abstract

Renal ischemia reperfusion damage is a severe syndrome that can develop after kidney transplants, kidney-targeting surgery, or other clinical situations that restrict blood flow to the kidneys. This study evaluated the effectiveness of the JAK1 inhibitor upadacitinib in lowering RIRI in a rat model. The rats were stratified into 4 groups after a 1 week acclimatization period. The study found that HMGBox and inflammatory substances like TNF-α and IL-6 impact RIRI. Upadacitinib's inhibition of the JAK1/STAT3 pathway minimized RIRI by significantly lowering these molecules. It also significantly reduced NF-κB activation, thereby reducing the inflammatory response and programmed cell death. The drug's ability to decrease BCL2/BAX level showed a significant reduction in kidney damage and apoptosis compared to the control group. The study concluded that upadacitinib may be able to prevent renal ischemia reperfusion and enhance patient outcomes. Further research is needed to examine its medicinal applications and efficacy.

References

1] Soares ROS, Losada DM, Jordani MC, Evora P, Castro-E- Silva O. Ischemia/reperfusion injury revisited: an overview of the latest pharmacological strategies. Int J Mol Sci 2019; vol. 20. MDPI AG.

[2] Furuichi K. WTYHKKIR of C and C in RIRInjuryDNPerspect 2002 O 482. doi: 10. 1358/dnp. 2002. 15. 8. 840067. P 12677185. role of cytokines and chemokines in renal ischemia-reperfusion injury. Drug News Perspect 2002;15(8):477e82.

[3] Baldwin AS. PERSPECTIVE SERIES NF-kB in defense and disease. J Clin Investig 2001;107.

[4] Wang C, Youle RJ. The role of mitochondria in apoptosis. Annu Rev Genet 2009;43:95e118.

[5] Dewson G, Kluck RM. Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis. J Cell Sci 2009; 122(16):2801e8.

[6] Hu X, li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinicvol. 6. Springer Nature; 2021. Signal transduction and targeted therapy.

[7] Chuang PY, He JC. JAK/STAT signaling in renal diseases. Kidney Int 2010;78:231e4.

[8] Huang Z, Jiang Q, Chen J, Liu X, Gu C, Tao T, et al. Therapeutic effects of upadacitinib on experimental autoimmune uveitis: insights from single-cell analysis. Invest Ophthalmol Vis Sci 2023;64(12).

[9] Mohamed MEF, Klünder B, Othman AA. Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication. Clinical Pharmacokinetics. Adis 2020;59:531e44.

[10] Kesarwani M, Huber E, Kincaid Z, Evelyn CR, Biesiada J, Rance M, et al. Targeting substrate-site in Jak 2 kinase prevents emergence of genetic resistance. Sci Rep 2015;5.

[11] Taldaev A, Rudnev VR, Nikolsky KS, Kulikova LI, Kaysheva AL. Molecular modeling insights into upadacitinib selectivity upon binding to JAK protein family. Pharmaceuticals 2022;15(1).

[12] Hussien YA, Abdalkadim H, Mahbuba W, Hadi NR, Jamil DA, Al-Aubaidy HA. The nephroprotective effect of lycopene on renal ischemic reperfusion injury: a mouse model. Indian J Clin Biochem 2020;35(4):474e81.

[13] Likhithaswamy HR, Madhushankari GS, Selvamani M, Mohan Kumar KP, Kokila G, Mahalakshmi S. Assessing the quality of long-term stored tissues in formalin and in paraffin-embedded blocks for histopathological analysis. J Microsc Ultrastruct 2022;10(1):23e9.

[14] Zhu Y, Yin X, Li JZL. Overexpression of microRNA-204-5p alleviates renal ischemia-reperfusion injury in mice through 50 MA'AEN JOURNAL FOR MEDICAL SCIENCES 2025;4:44e51 blockage of Fas/FasL pathway. Exp Cell Res 2019;381(2): 208e14. https://doi.org/10.1016/j.yexcr.2019.04.023. Epub 2019 Apr 19. PMID: 31009621. 31009621.

[15] Chai Y, Zhu K, Li C, Wang X, Shen J, Yong F, et al. Dexmedetomidine alleviates cisplatineinduced acute kidney injury by attenuating endoplasmic reticulum stresseinduced apoptosis via the a2AR/PI3K/AKT pathway. Mol Med Rep 2020;21(3):1597e605.

[16] Kocak A, Koldemir Gunduz M, Kaymak G, Aydin E. Effects of upadacitinib and PD29 on oxidative damage and inflammation in bleomycin-induced scleroderma model kidney tissues. Marmara Med J [Internet] 2024;37(1):72e9. Available from: https://dergipark.org.tr/tr/pub/marumjhttp://doi.org/ 10.5472/marumj.1381649.

[17] Anbar HS, Shehab NG, El-Rouby NMM, Ansari MA, Chenoth H, Majeed M, et al. Upadacitinib protects against cisplatin-induced renal and hepatic dysfunction without impairing its anticancer activity. Eur J Pharmaceut Sci 2022:172.

[18] Tanaka Y, Luo Y, O'Shea JJ, Nakayamada S. Janus kinasetargeting therapies in rheumatology: a mechanisms-based approach. Vol. 18. Nature Rev Rheumatol 2022:133e45. Nature Research.

[19] Wang J, Macoritto M, Guay H, Davis JW, Levesque MC, Cao X. The clinical response of upadacitinib and risankizumab is associated with reduced inflammatory bowel disease anti-TNF-a inadequate response mechanisms. Inflamm Bowel Dis [Internet] 2023;29(5):771e82.

[20] Makris K, Spanou L. Acute kidney injury: definition, pathophysiology and clinical phenotypes. Acute Kidney Injury Clin Biochem Rev 2016;37.

[21] Younus LA. The potential impact of Ibuprofen on level of IL6. Maaen J Med Sci 2024;3(1).

[22] Huang B, Lang X, Li X. The role of IL-6/JAK2/STAT3 signaling pathway in cancers. Front Oncol 2022;vol. 12. Frontiers Media S.A.

[23] Mohamed MEF, Beck D, Camp HS, Othman AA. Preferential inhibition of JAK1 relative to JAK3 by upadacitinib: exposure-response analyses of ex vivo data from 2 phase 1 clinical trials and comparison to tofacitinib. J Clin Pharmacol 2020; 60(2):188e97.

[24] Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, Kaya Z, et al. High-mobility group box-1 in ischemiareperfusion injury of the heart. Circulation 2008;117(25): 3216e26.

[25] Liu Q, Xie W, Wang Y, Chen S, Han J, Wang L, et al. JAK2/ STAT1-mediated HMGB1 translocation increases inflammation and cell death in a ventilator-induced lung injury model. Lab Invest 2019;99(12):1810e21.

[26] Gremese E, Alivernini S, Tolusso B, Zeidler MP, Ferraccioli G. JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. J Leukoc Biol 2019;106:1063e8. John Wiley and Sons Inc.

[27] X-D Ying 1 GWHA. Sodium butyrate relieves lung ischemiareperfusion injury by inhibiting NF-kB and JAK2/STAT3 signaling pathways. Eur Rev Med Pharmacol Sci 2021;25(1): 413e22. doi: 1026355/eurrev_202101_24409.

[28] Sepúlveda P, Encabo A, Carbonell-Uberos F, Minana MD. ~ BCL-2 expression is mainly regulated by JAK/STAT3 pathway in human CD34þ hematopoietic cells [1]. Cell Death Differ 2007;14:378e80.

[29] Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, et al. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal celleinduced protection of AML. Blood 2017;130(6):789e802.

[30] Takei H, Coelho-Silva JL, Tavares Leal C, Queiroz Arantes, Rocha A, Mantello Bianco T, et al. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms. Cancer Sci 2022;113(2):597e608.

[31] Yuan X, Ni L, Li H, Zhang D, Zhou K. The neural correlates of individual differences in numerosity perception: a voxelbased morphometry study. iScience 2023;26(8).

[32] Brosius FC, He JC. JAK inhibition and progressive kidney disease. Vol. 24, Current opinion in nephrology and hypertension. Lippincott Williams and Wilkins; 2015. p. 88e95.

[33] Neria F, Castilla MA, Sanchez RF, Gonzalez Pacheco FR, Deudero JJP, Calabia O, et al. Inhibition of JAK2 protects renal endothelial and epithelial cells from oxidative stress and cyclosporin A toxicity. Kidney Int 2009;75(2): 227e34.

[34] Vadimov Teplova N, Ivanovna Bairova K, Evsikov E, Gabitovich Dzheksembekov A, Sergeevich Melnichenko A. Open Peer Review on Qeios [Review] Drug-induced causes of renal damage and dysfunction in patients with complicated COVID-19. Available from: https://doi.org/10.32388/ MN2G71.

Download

Share

COinS